The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: Occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers

Inbar Gal, Ruth Gershoni Baruch, Daniel Haber, Efrat Dagan, Shlomit Eisenberg-Barzilai, Jamal Zidan, Eitan Friedman

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Few mutations have been described in BRCA1 and BRCA2 in high-risk non-Ashkenazi Jews. In a Libyan family the 1100delAT BRCA1 mutation was detected and the 8765delAG BRCA2 mutation was previously described in two Jewish-Yemenite-families. In this study, the rate of these mutations in high-risk Jews of North African and Yemenite origin was assessed, and the BRCA1-linked haplotype of Jewish and non-Jewish 1100delAT mutation carriers were compared. Genotyping included 64 high-risk Yemenite women (tested only for the BRCA2 mutation) and 147 high-risk North African women, tested for both mutations. PCR amplification was followed by either restriction enzyme digestion or DGGE or dHPLC analyses and direct sequencing. For haplotyping, 5 BRCA1-linked markers were used. Neither the 1100delAT BRCA1 nor the 8765delAG BRCA2 mutations were detected in any non-Ashkenazi individual. The haplotype of the non-Jewish 1100delAG mutation carrier differed from that of the Jewish-Libyan mutation carriers. We conclude that both 1100delAT BRCA1 and 8765delAG BRCA2 mutations occur rarely in high-risk non-Ashkenazi Jews, and while the latter seems to be a founder mutation in some populations, the former occurs on a different background in ethnically diverse families.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalFamilial Cancer
Volume3
Issue number1
DOIs
StatePublished - 2004
Externally publishedYes

Bibliographical note

Funding Information:
This study was performed in part in fulfillment of the requirements of Inbar Gal towards her masters degree at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel. This study was sponsored in part by a grant from the Middle East Cancer Consortium (MECC) to Eitan Friedman.

Funding

This study was performed in part in fulfillment of the requirements of Inbar Gal towards her masters degree at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel. This study was sponsored in part by a grant from the Middle East Cancer Consortium (MECC) to Eitan Friedman.

FundersFunder number
Middle East Cancer Consortium

    Keywords

    • BRCA1/2
    • Founder mutations
    • Genetic isolate
    • High-risk non-Ashkenazim
    • Shared haplotype

    Fingerprint

    Dive into the research topics of 'The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: Occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers'. Together they form a unique fingerprint.

    Cite this